Literature DB >> 17624826

Tuberculosis and HIV infection: the global setting.

Paul Nunn1, Alasdair Reid, Kevin M De Cock.   

Abstract

Tuberculosis (TB) and human immunodeficiency virus (HIV) infection make each other's control significantly more difficult. Coordination in addressing this "cursed duet" is insufficient at both global and national levels. However, global policy for TB/HIV coordination has been set, and there is consensus around this policy from both the TB and HIV control communities. The policy aims to provide all necessary care for the prevention and management of HIV-associated TB, but its implementation is hindered by real technical difficulties and shortages of resources. All major global-level institutions involved in HIV care and prevention must include TB control as part of their corporate policy. Country-level decision makers need to work together to expand both TB and HIV services, and civil society and community representatives need to hold those responsible accountable for their delivery. The TB and HIV communities should join forces to address the health-sector weaknesses that confront them both.

Entities:  

Mesh:

Year:  2007        PMID: 17624826     DOI: 10.1086/518660

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

2.  Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.

Authors:  Patrice Severe; Marc Antoine Jean Juste; Alex Ambroise; Ludger Eliacin; Claudel Marchand; Sandra Apollon; Alison Edwards; Heejung Bang; Janet Nicotera; Catherine Godfrey; Roy M Gulick; Warren D Johnson; Jean William Pape; Daniel W Fitzgerald
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 3.  Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge.

Authors:  Robert Loddenkemper; Barbara Hauer
Journal:  Dtsch Arztebl Int       Date:  2010-01-07       Impact factor: 5.594

Review 4.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

5.  Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.

Authors:  Shabir A Madhi; Sharon Nachman; Avy Violari; Soyeon Kim; Mark F Cotton; Raziya Bobat; Patrick Jean-Philippe; George McSherry; Charles Mitchell
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

6.  Intrafamilial cluster of pulmonary tuberculosis due to Mycobacterium bovis of the African 1 clonal complex.

Authors:  S Godreuil; E Jeziorski; A L Bañuls; T Fraisse; P Van de Perre; M L Boschiroli
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

7.  Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients.

Authors:  P Tabarsi; E Chitsaz; A Moradi; P Baghaei; P Farnia; M Marjani; M Shamai; M Amiri; S Nikaein; D Mansouri; M Masjedi; F Altice
Journal:  Int J STD AIDS       Date:  2012-09       Impact factor: 1.359

8.  Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses.

Authors:  S Takuva; D Westreich; C N Menezes; L McNamara; I Sanne; L Page-Shipp; M Maskew
Journal:  Int J Tuberc Lung Dis       Date:  2012-08-03       Impact factor: 2.373

9.  Tetrahdroxysqualene from Rhus taitensis shows antimycobacterial activity against Mycobacterium tuberculosis.

Authors:  Jeffrey C Noro; Louis R Barrows; Osia G Gideon; Chris M Ireland; Michael Koch; Teatulohi Matainaho; Pius Piskaut; Christopher D Pond; Tim S Bugni
Journal:  J Nat Prod       Date:  2008-08-19       Impact factor: 4.050

Review 10.  Exploring prospects of novel drugs for tuberculosis.

Authors:  Saskia Janssen; Rajesh Jayachandran; Lulama Khathi; Jakob Zinsstag; Martin P Grobusch; Jean Pieters
Journal:  Drug Des Devel Ther       Date:  2012-09-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.